Book Value per Share: longboardpharma.com (LBPH)

Longboard Pharmaceuticals (LBPH) - corporate logo

Longboard Pharmaceuticals focuses on epilepsy therapy, relying on Bexicaserin trials and external funding. The reported book value per share demonstrates financial stability, and 7.12 captures the magnitude of this parameter. Longboard Pharmaceuticals is attracting leading neurobiologists to develop innovative drugs. The current ecosystem relies on FDA support and the influx of investment following successful clinical trial phases.

Longboard Pharmaceuticals Inc (LBPH) Equity per Share: for the period 07/04/2022 - 12/07/2024

longboardpharma.com - analytical breakdowns and key metrics (LBPH)

- price and consensus price forecast:
Price Chart Longboard Pharma|LBPH - Forecast Levels Chart
- market capitalization data:
Market Capitalization Longboard Pharmaceuticals, Inc.|LBPH - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Longboard Pharmaceuticals|LBPH - Accounting Capitalization|Market Capitalization to Book Value Ratio longboardpharma.com|LBPH - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital|Short-Term Debt to Equity Longboard Pharmaceuticals, Inc.|LBPH - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Longboard Pharmaceuticals, Inc.
Fundamental company valuation:Longboard Pharma, LBPH
Manufactured products of Longboard Pharmaceuticals, Inc.

Capital analysis allows for the filtering of speculative noise by revealing the actual value of net assets minus liabilities, which reflects the fundamental book value of a common share. For Longboard Pharmaceuticals (LBPH), which is developing drugs for severe epilepsy, the trend of this indicator confirms the financial stability of the business during its active growth phase and determines a fair entry threshold without overpaying for assets.

Competitor analysis for Longboard Pharmaceuticals

Net Assets per Single Share Biogen Corp|NBIX - Share Book Value|Book Value per Share Regencell Bioscience RGC|AXSM (axsome.com) - Accounting Value of a Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|TRVI (Trevi Corp) - Net Asset Value per Share|Net Assets per Single Share Praxis Precision Medicines|Net Assets per Single Share AVXL|CeriBell - Net Assets per Single Share|Net Asset Value per Share PRTA (Prothena Corporation)|ALEC - Net Assets per Single Share|Equity per Share Annexon Biosciences Inc. ANNX|Book Value per Share OMER|NGNE - Book Value of One Share|AC Immune SA (ACIU) - Book Value per Share|VYGR (Voyager Therapeutics Inc) - Net Assets per Single Share|Net Assets per Single Share NMRA (Neumora Therapeutics Inc)|Net Asset Value per Share Scilex Holding Company, Inc.|Book Value per Share TVGN|Book Value per Share ACOG (alphacognition.com)|Net Assets per Single Share Cognition Therapeutics|Accounting Value of a Share Inhibikase Therapeutics Inc IKT|Cassava (SAVA) - Book Value per Share|Assertio Holdings, Inc. (ASRT) - Equity per Share|Accounting Value per Share coyatherapeutics.com COYA|VTGN (Vistagen) - Accounting Value of a Share|Net Assets per Single Share Ovid Therapeutics Inc OVID|Share Book Value Acumen Pharmaceuticals Inc.|CervoMed Inc (CRVO) - Book Value per Share|Accounting Value of a Share alteritytherapeutics.com (ATHE)|Book Value per Share CLNN (Clene)|PepGen Inc - Book Value per Share|Net Assets per Single Share Jupiter Neurosciences Inc (JUNS)|RLMD: Accounting Value of a Share|ANVS (Annovis Bio Corp) - Net Assets per Single Share|Grace Therapeutics (GRCE) - Accounting Value per Share|AIFF (Firefly Neuroscience, Inc) - Book Value per Share|Book Value per Share ANEW Medical, Inc.|Book Value per Share NRSN (NeuroSense Therapeutics)|Accounting Value per Share Reviva Pharmaceuticals Holdings Inc. (RVPH)|MTVA: Book Value per Share|NRXS - Net Asset Value per Share|Helius Medical Technologies Inc. - Accounting Value per Share|Passage Bio, Inc. (PASG) - Book Value per Share|NEUP - Accounting Value per Share|Minerva Neurosciences Inc (NERV) - Book Price of a Share|ATHA: Book Value per Share|Net Assets per Share Addex|Book Value per Share ALZN (Alzamend Neuro, Inc.)|Accounting Value per Share cyclerion.com (CYCN)|Book Value per Share PTIX (Protagenic Therapeutics, Inc.)|Pasithea Therapeutics Corp - Book Value per Share|CRGT - Net Assets per Single Share|ATXI: Net Assets per Single Share|Brainstorm Cell - Net Assets per Single Share|CARA (caratherapeutics.com) - Net Assets per Share|Net Assets per Single Share Chromocell Therapeutics Corp.|Net Assets per Single Share Eliem|Book Value per Share Intra-Cellular Therapies (ITCI)|Net Assets per Single Share MRNS (Marinus Pharma)|NKGen Biotech, Inc. (NKGN) - Net Assets per Single Share|Share Book Value neurobopharma.com NRBO|Book Value per Share Sage Therapeutics (SAGE)|SNPX: Accounting Value of a Share|Net Assets per Single Share Trevena, Inc|Vigil Neuroscience, Inc. (VIGL) - Equity per Share|Book Value per Share WENA (Anew Medical)|Net Asset Value per Share cerevel.com (CERE)